RAAS inhibitors are associated with a better chance of surviving of inpatients with Covid-19 without a diagnosis of diabetes mellitus, compared with similar patients who did not require antihypertensive therapy or were treated with other antihypertensives

RAAS inhibitors are associated with a better chance of surviving of inpatients with Covid-19 without a diagnosis of diabetes mellitus, compared with similar patients who did not require antihypertensive therapy or were treated with other antihypertensives

PurposeThe effect of renin-angiotensin-aldosterone system (RAAS) inhibitors in combination with COVID-19 and diabetes mellitus (DM) remains unknown. We assessed the risk of death in COVID-19 inpatients based on the presence or absence of DM, arterial hypertension (AH) and the use of RAAS inhibitors...

Full description

Bibliographic Details
Main Authors: Mykola Khalangot, Nadiia Sheichenko, Vitaly Gurianov, Tamara Zakharchenko, Victor Kravchenko, Mykola Tronko
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-01-01
Series:Frontiers in Endocrinology
Subjects:
COVID-19
RAAS inhibitors
mortality
diabetes mellitus
angiotensin-converting-enzyme inhibitors (ACEi)
angiotensin II receptor blockers (ARBs)
Online Access:https://www.frontiersin.org/articles/10.3389/fendo.2023.1077959/full

Internet

https://www.frontiersin.org/articles/10.3389/fendo.2023.1077959/full

Similar Items